Cargando…

Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma

Hepatocellular carcinoma is a common gastrointestinal malignancy with a high mortality rate and limited treatment options. Molecularly targeted drugs combined with immune checkpoint inhibitors have shown unique advantages over single-agent applications, significantly prolonging patient survival. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Shuqi, Wang, Mengchao, Zeng, Chuanxiu, Ou, Yan, Zhao, Lu, Wang, Dong, Chen, Liwei, Kong, Fanming, Yi, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248438/ https://www.ncbi.nlm.nih.gov/pubmed/37305582 http://dx.doi.org/10.3389/fonc.2023.1197698

Ejemplares similares

Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma
por: Xu, Yiwei, et al.
Publicado: (2023)

Research Progress of Antibody–Drug Conjugate Therapy for Advanced Gastric Cancer
por: Wang, Na, et al.
Publicado: (2022)

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
por: Zhao, Lu, et al.
Publicado: (2022)

Research Progress of DUB Enzyme in Hepatocellular Carcinoma
por: Zhao, Jie, et al.
Publicado: (2022)

Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research
por: Wu, Shilun, et al.
Publicado: (2022)

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
por: Zhang, Wenxiang, et al.
Publicado: (2021)

Application of Immunotherapy in Hepatocellular Carcinoma
por: Miao, Lele, et al.
Publicado: (2021)

Editorial: Immunotherapy in Hepatocellular Carcinoma
por: Li, Bin, et al.
Publicado: (2021)

Role of Forkhead Box O Proteins in Hepatocellular Carcinoma Biology and Progression (Review)
por: Yang, Shaojie, et al.
Publicado: (2021)

Hepatocellular Carcinoma Differentiation: Research Progress in Mechanism and Treatment
por: Song, Jianning, et al.
Publicado: (2022)

Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
por: Zhong, Cheng, et al.
Publicado: (2021)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
por: He, Yuqing, et al.
Publicado: (2021)

Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
por: Peng, Xuenan, et al.
Publicado: (2023)

Research progress of spontaneous ruptured hepatocellular carcinoma: Systematic review and meta-analysis
por: Wang, Chunling, et al.
Publicado: (2022)

Research Progress on Long Noncoding RNAs and N6-Methyladenosine in Hepatocellular Carcinoma
por: Zhang, Wenjie, et al.
Publicado: (2022)

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2020)

Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Tiantian, et al.
Publicado: (2022)

Research progress of nanovaccine in anti-tumor immunotherapy
por: Yao, Min, et al.
Publicado: (2023)

Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Chiang, Chi-Leung, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: A systematic review and meta analysis
por: Zhong, Yu, et al.
Publicado: (2022)

Targeting Long Non-Coding RNAs in Hepatocellular Carcinoma: Progress and Prospects
por: Lin, Xinrong, et al.
Publicado: (2021)

Research progress of circulating non-coding RNA in diagnosis and treatment of hepatocellular carcinoma
por: You, Junqi, et al.
Publicado: (2023)

Progress of MRI Radiomics in Hepatocellular Carcinoma
por: Gong, Xue-Qin, et al.
Publicado: (2021)

Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?
por: Gao, Xiaoni, et al.
Publicado: (2023)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis
por: Qin, Jian, et al.
Publicado: (2022)

Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma
por: Yang, Yang, et al.
Publicado: (2021)

A Novel Nine-lncRNA Risk Signature Correlates With Immunotherapy in Hepatocellular Carcinoma
por: Nie, Ye, et al.
Publicado: (2021)

Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling
por: Yu, Chao, et al.
Publicado: (2023)

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

An Integrative Analysis Reveals the Underlying Association Between CTNNB1 Mutation and Immunotherapy in Hepatocellular Carcinoma
por: Mo, Zhuomao, et al.
Publicado: (2020)

The Clinical Observation of Acupuncture Combined With Antiemetic Drugs in the Prevention and Treatment of CINV in Breast Cancer Patients
por: Kong, Fanming, et al.
Publicado: (2022)

ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma
por: Liu, Fahui, et al.
Publicado: (2022)

ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma
por: Zhang, Yu, et al.
Publicado: (2022)

Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma
por: Zhu, Jun, et al.
Publicado: (2022)

Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy
por: Li, Qian, et al.
Publicado: (2023)

Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment
por: Yu, Siting, et al.
Publicado: (2022)

Overexpression of GINS4 Is Associated With Tumor Progression and Poor Survival in Hepatocellular Carcinoma
por: Zhang, Ziying, et al.
Publicado: (2021)

Immune checkpoint inhibitors in cervical cancer: Current status and research progress
por: Xie, Yunkai, et al.
Publicado: (2022)

Cuproptosis-related genes score: A predictor for hepatocellular carcinoma prognosis, immunotherapy efficacy, and metabolic reprogramming
por: Nie, Guilin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2qtvfk9h1fn07lsrs9v1ota4on